



UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press Release

UCB APPOINTS CHIEF FINANCIAL OFFICER

Brussels, October 18th, 2004 - UCB announces the appointment of Luc Missorten as Chief Financial Officer of the Group.

Luc Missorten joined UCB in February 2004 as General Manager of UCB Pharma Spain in Barcelona. Prior to joining UCB, he was Executive Vice President and Chief Financial Officer of Interbrew.

The nomination is taking effect as of November 1st, 2004. Luc Missorten will be reporting to Georges Jacobs, Chairman of the Executive Committee.

About the UCB Group

UCB (www.ucb-group.com) is a global pharmaceutical and specialty chemical leader with headquarters in Brussels, Belgium. Through its Pharma division, the company is focused on innovative solutions for human healthcare. UCB Pharma is a global biopharmaceutical player, specialising in the fields of central nervous system disorders, allergy and respiratory disease, immune and inflammatory disorders and oncology. UCB Pharma's key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), and Tussionex® (antitussive). UCB Pharma employs over 8,000 people operating in over 100 countries, and in 2003 achieved sales of €1.5 billion. UCB is listed on Euronext Brussels, and achieved sales of €3 billion and a net profit of €340 million in 2003.

On October 1st, 2004, UCB announced the sale of its Surface Specialties business, representing 4,500 people, to enable the Company to focus on its biopharmaceutical activities.

Information:

UCB - Press contact

Laurence Battaille
Head of Corporate Communication

Tel.: +32 (2) 559 95 88

UCB - Investor Relations contact

Arnaud Denis
Investor Relations Manager

Tel.: +32 (2) 559 92 64